ArticleJournal of the science of food and agriculture2026
The regulatory frameworks surrounding CRISPR-edited papaya and their impact on international commerce.
Article in Journal of the science of food and agriculture, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The papaya tree (Carica papaya L.), native to the Americas, is cultivated in tropical regions and holds substantial economic importance, with an estimated export volume of 365 000 t in 2023. However, diseases caused by viruses, fungi, bacteria, and nematodes can lead to severe losses. Among the more than 38 known viral diseases affecting papaya, only a few poses serious threats to cultivation, notably Papaya Ringspot, Papaya Mosaic, and Papaya Sticky Disease (PSD). Emerging technologies, particularly CRISPR/Cas9 gene editing, offer promising avenues to enhance plant resistance. This study examines regulatory paradigms in key papaya-producing and importing countries, highlighting the need for international regulatory harmonization to reduce trade barriers and improve market access for CRISPR-edited cultivars. We demonstrate the feasibility of CRISPR-based genome editing in papaya (Carica papaya L.) by targeting phytoene desaturase as a proof-of-concept marker gene and β-1,3-glucanase, a resistance gene identified through proteomic profiling of host-pathogen interactions during infection by the papaya meleira virus (PMeV and PMeV2) complex. This virus complex causes PSD, a major threat to papaya production, rendering the fruit commercially unviable due to negative effects on texture and flavor as well as inhibiting the formation of benzyl isothiocyanate (BITC), and the fruits become susceptible to fruit flies, which are quarantine pests. Despite extensive traditional breeding efforts, resistant papaya genotypes have yet to be identified, underscoring the need for innovative approaches. However, translating advancements into commercial applications remains challenging due to the diverse and often inconsistent regulatory frameworks governing genome-edited crops across different jurisdictions. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.